B-MS extends range of Glucophage XR
The US Food and Drug Administration has approved Glucophage XR(metformin HCl extended release tablets) 750mg tablet, a new dosage strength of one of the firm's leading products.
Glucophage XR was launched in a 500mg formulation in October 2000 for use together with diet and exercise as initial drug therapy to improve glycemic control for adults 17 years and older with type 2 diabetes, when diet and exercise are not enough. The new formulation is intended to allow a hike in dose in patients who do not respond to the lower dose and, like its 500mg counterpart, may also be used in combination with a sulfonylurea or insulin to improve glycemic control.
The Glucophage XR range was developed to help B-MS protect its lucrative market for the immediate-release version of the drug, which has since lost patent protection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze